Sitagliptin / Metformin hydrochloride Sun
Nchi: Umoja wa Ulaya
Lugha: Kimalta
Chanzo: EMA (European Medicines Agency)
Taarifa za kipeperushi
(PIL)
06-06-2024
Tabia za bidhaa
(SPC)
06-06-2024
Ripoti ya Tathmini ya umma
(PAR)
07-06-2024
Viambatanisho vya kazi:
sitagliptin fumarate, metformin hydrochloride
Inapatikana kutoka:
Sun Pharmaceutical Industries Europe B.V.
ATC kanuni:
A10BD07
INN (Jina la Kimataifa):
sitagliptin, metformin hydrochloride
Kundi la matibabu:
Drogi użati fid-dijabete
Eneo la matibabu:
Diabetes Mellitus, Tip 2
Matibabu dalili:
For adult patients with type 2 diabetes mellitus:Sitagliptin/Metformin hydrochloride SUN is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. Sitagliptin/Metformin hydrochloride SUN is indicated in combination with a sulphonylurea (i. , terapija ta 'kumbinazzjoni tripla) bħala żieda mad-dieta u l-eżerċizzju f'pazjenti mhux ikkontrollati adegwatament fuq id-doża massima ttollerata ta' metformin u sulphonylurea. Sitagliptin/Metformin hydrochloride SUN is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (PPARγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPARγ agonist. Sitagliptin/Metformin hydrochloride SUN is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
Idhini hali ya:
Awtorizzat
Idhini ya tarehe:
2023-03-31
Taarifa za kipeperushi
The website encountered an unexpected error. Try again later.
Tabia za bidhaa
The website encountered an unexpected error. Try again later.
